TY - JOUR
T1 - Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery
AU - Moghimi, Sasan
AU - Zandian, Mehdi
AU - Latifi, Golshan
AU - Amini, Heydar
AU - Eslami, Yadollah
AU - Zarei, Reza
AU - Fakhraie, Ghasem
AU - Nouri-Mahdavi, Kouros
PY - 2012
Y1 - 2012
N2 - Purpose: To explore changes in central macular thickness (CMT) after a two-month period of glaucoma therapy with topical latanoprost after uneventful phacoemulsification. Methods: Forty-one eyes of 31 patients with primary open angle or pseudoexfoliative glaucoma who required glaucoma medications after cataract surgery were prospectively enrolled. All eyes had undergone uneventful phacoemulsification with intraocular lens implantation at least 4 months before initiation of latanoprost. After a complete ophthalmic examination, spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) were performed at baseline before starting latanoprost. All eyes received latanoprost for 2 months, and clinical examinations were repeated one and two months afterwards; OCT and FA were repeated after 2 months. Outcome measures were CMT and loss of more than 2 lines of best corrected visual acuity (BCVA). Results: Mean patient age was 71.6±7.8 years. Intraocular pressure decreased from 21.5±3.4 mmHg to 14.4±2.6 mmHg (p<0.001) at 2 months. None of the eyes developed reduction of BCVA exceeding 2 lines, or angiographic cystoid macular edema (CME). Likewise no significant change was noted in CMT (249.9±29.8 vs 248.8±30.7μm), average macular thickness (274.5±15.0 vs 273.8±17.0μm), or macular volume (9.6±1.0 vs 9.6±1.1μm2) after treatment as compared to baseline (P>0.05 for all comparisons). Conclusion: Topical use of latanoprost later than 4 months after uncomplicated cataract surgery does not seem to predispose to increased macular thickness or CME and may safely be used in this setting.
AB - Purpose: To explore changes in central macular thickness (CMT) after a two-month period of glaucoma therapy with topical latanoprost after uneventful phacoemulsification. Methods: Forty-one eyes of 31 patients with primary open angle or pseudoexfoliative glaucoma who required glaucoma medications after cataract surgery were prospectively enrolled. All eyes had undergone uneventful phacoemulsification with intraocular lens implantation at least 4 months before initiation of latanoprost. After a complete ophthalmic examination, spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) were performed at baseline before starting latanoprost. All eyes received latanoprost for 2 months, and clinical examinations were repeated one and two months afterwards; OCT and FA were repeated after 2 months. Outcome measures were CMT and loss of more than 2 lines of best corrected visual acuity (BCVA). Results: Mean patient age was 71.6±7.8 years. Intraocular pressure decreased from 21.5±3.4 mmHg to 14.4±2.6 mmHg (p<0.001) at 2 months. None of the eyes developed reduction of BCVA exceeding 2 lines, or angiographic cystoid macular edema (CME). Likewise no significant change was noted in CMT (249.9±29.8 vs 248.8±30.7μm), average macular thickness (274.5±15.0 vs 273.8±17.0μm), or macular volume (9.6±1.0 vs 9.6±1.1μm2) after treatment as compared to baseline (P>0.05 for all comparisons). Conclusion: Topical use of latanoprost later than 4 months after uncomplicated cataract surgery does not seem to predispose to increased macular thickness or CME and may safely be used in this setting.
KW - Cystoid macular edema
KW - Latanoprost
KW - Macular thickness
UR - http://www.scopus.com/inward/record.url?scp=84872016319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872016319&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84872016319
SN - 2008-2010
VL - 7
SP - 289
EP - 294
JO - Journal of Ophthalmic and Vision Research
JF - Journal of Ophthalmic and Vision Research
IS - 4
ER -